Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8326 to 8340 of 8903 results

  1. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 (TA201)

    This guidance has been updated and replaced by NICE technology appraisal guidance 278.

    Withdrawn guidance

  2. Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab (TA202)

    This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Withdrawn guidance

  3. Retigabine for the adjunctive treatment of partial onset seizures in epilepsy (TA232)

    The guidance has been withdrawn because GlaxoSmithKline has discontinued retigabine (Trobalt) due to limited usage.

    Withdrawn guidance

  4. Golimumab for the treatment of ankylosing spondylitis (TA233)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

    Withdrawn guidance

  5. Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (TA234)

    This guidance has been updated and replaced by NICE technology appraisal guidance 280.

    Withdrawn guidance

  6. Ranibizumab for the treatment of diabetic macular oedema (TA237)

    This guidance has been updated and replaced by NICE technology appraisal guidance 274.

    Withdrawn guidance

  7. Sorafenib for the treatment of advanced hepatocellular carcinoma (TA189)

    This guidance has been replaced by NICE technology appraisal guidance 474.

    Withdrawn guidance

  8. Alzheimer's disease (mild to moderate) - donepezil, rivastigmine and galantamine (TA19)

    This guidance has been replaced by NICE technology appraisal guidance 111.

    Withdrawn guidance

  9. Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (terminated appraisal) (TA194)

    This guidance has been updated and replaced by NICE guideline CG175.

    Withdrawn guidance

  10. Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA196)

    This guidance has been replaced by NICE technology appraisal guidance 326.

    Withdrawn guidance

  11. Liraglutide for the treatment of type 2 diabetes mellitus (TA203)

    This guidance has been updated and replaced by NICE guideline NG28.

    Withdrawn guidance

  12. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA205)

    This guidance has been updated and replaced by NICE technology appraisal guidance 293.

    Withdrawn guidance

  13. Diabetes (type 2) - pioglitazone (TA21)

    This guidance has been replaced by NICE technology appraisal guidance 63 [Replaced by NICE guideline CG66].

    Withdrawn guidance

  14. Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer (TA26)

    This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].

    Withdrawn guidance

  15. Adalimumab for the treatment of moderate to severe ulcerative colitis (terminated appraisal) (TA262)

    This guidance has been updated and replaced by NICE technology appraisal guidance 329.

    Withdrawn guidance